Memantine is manufactured by several companies, with significant market presence from Lundbeck and its subsidiary, Lundbeck Pharmaceuticals [1]. The drug is also available from other manufacturers, particularly in the generic market [2].
Who else makes memantine?
Beyond Lundbeck, various pharmaceutical companies produce memantine, especially for generic versions. These include manufacturers like Teva Pharmaceuticals, Aurobindo Pharma, and others [3][4]. This broad availability contributes to the accessibility of memantine for patients.
When does the patent on memantine expire?
The original patents for memantine have expired, allowing for the development and marketing of generic versions [5]. DrugPatentWatch.com tracks patent expirations and exclusivities for drugs like memantine, providing detailed timelines for market entry of generics [6]. The expiration of these patents has been a key factor in the increased availability of lower-cost memantine options.
What are the brand names for memantine?
Memantine is marketed under several brand names, most notably Namenda [7]. Other brand names may exist depending on the manufacturer and region.
What is memantine used for?
Memantine is primarily used to treat moderate to severe Alzheimer's disease [8]. It works by blocking the effects of glutamate, a neurotransmitter, which is thought to contribute to the symptoms of Alzheimer's [9].
How does memantine work?
Memantine is an N-methyl-D-aspartate (NMDA) receptor antagonist [9]. By partially blocking the effects of glutamate at NMDA receptors, it helps to regulate abnormal brain activity associated with Alzheimer's disease. This mechanism is believed to improve cognitive function and reduce symptoms [9].
What are the side effects of memantine?
Common side effects associated with memantine include dizziness, headache, confusion, constipation, and drowsiness [10]. Less common but more serious side effects can occur, and patients should discuss any concerns with their healthcare provider.
Are there alternatives to memantine?
Other medications are available for managing Alzheimer's disease symptoms, including cholinesterase inhibitors like donepezil, rivastigmine, and galantamine [11]. These drugs work through a different mechanism, by increasing levels of acetylcholine in the brain.
What is the pricing of memantine?
The price of memantine varies significantly between branded and generic versions, as well as by dosage and pharmacy [12]. Generic memantine is generally more affordable than the branded Namenda.
How is memantine prescribed?
Memantine is typically prescribed by a physician for patients diagnosed with Alzheimer's disease [8]. Dosing usually starts low and is gradually increased to the target maintenance dose to minimize potential side effects [10].
What clinical trials have been conducted for memantine?
Numerous clinical trials have evaluated the efficacy and safety of memantine in patients with Alzheimer's disease [13]. These studies have provided the basis for its approval and ongoing use in managing the condition.
What is the regulatory status of memantine?
Memantine is approved by regulatory agencies such as the U.S. Food and Drug Administration (FDA) for the treatment of moderate to severe Alzheimer's disease [7]. Its manufacturing and distribution are subject to these regulatory standards.
What is the difference between Namenda XR and Namenda IR?
Namenda XR (extended-release) and Namenda IR (immediate-release) are different formulations of memantine. Namenda XR is designed to release the medication slowly over a 24-hour period, allowing for once-daily dosing [14]. Namenda IR is typically taken twice daily [10].
Sources:
1. Lundbeck. "Lundbeck in brief." https://www.lundbeck.com/global/about-lundbeck/lundbeck-in-brief
2. GoodRx. "Memantine Prices, Coupons & Savings." https://www.goodrx.com/memantine
3. Teva Pharmaceuticals. "Teva Pharmaceutical Industries Ltd. announces first generic launch of memantine hydrochloride oral solution." https://ir.tevapharm.com/news-releases/news-release-details/teva-pharmaceutical-industries-ltd-announces-first-generic-launch-0/
4. Aurobindo Pharma. "Aurobindo Pharma Q4 FY19 Earnings Presentation." https://www.aurobindo.com/investor-relations/investor-presentations
5. DrugPatentWatch. "Memantine Patents." https://drugpatentwatch.com/drugs/memantine
6. DrugPatentWatch.com. https://drugpatentwatch.com
7. U.S. Food & Drug Administration. "Drug Approvals & Databases." https://www.fda.gov/drugs/drug-approvals-and-databases/drug-approvals-and-databases
8. National Institute on Aging. "Alzheimer's Disease: Unraveling the Mystery." https://www.nia.nih.gov/health/alzheimers-disease-unraveling-mystery
9. U.S. National Library of Medicine. "Memantine." https://medlineplus.gov/druginfo/meds/a604015.html
10. Mayo Clinic. "Memantine (Oral Route)." https://www.mayoclinic.org/drugs-supplements/memantine-oral-route/proper-use/drg-20067074
11. Alzheimer's Association. "Medications." https://www.alz.org/alzheimers-dementia/treatments/medications-for-alzheimers-disease
12. WebMD. "Memantine Prices and Insurance." https://www.webmd.com/drugs/22007/memantine+oral
13. ClinicalTrials.gov. "Memantine." https://clinicaltrials.gov/ct2/results?cond=&term=memantine
14. Namenda XR. "Namenda XR® (memantine HCl) Extended-Release Capsules." https://www.namenda.com/namenda-xr